Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? by Y Gert van der Meer et al.
van der Meer et al. Critical Care 2014, 18:502
http://ccforum.com/content/18/5/502VIEWPOINTShould we stop prescribing metoclopramide as a
prokinetic drug in critically ill patients?
Y Gert van der Meer1, Willem A Venhuizen1, Daren K Heyland2 and Arthur RH van Zanten3*Abstract
Regulatory agencies in North America and Europe
recently re-evaluated the safety of metoclopramide.
This re-evaluation resulted in recommendations
and restrictions in order to minimise the risk of
neurological and other adverse reactions associated
with the use of metoclopramide. In the ICU, off-label
prescription of metoclopramide is common. We have
reviewed the evidence for safety, effectiveness and
dosing of metoclopramide in critically ill patients.
Furthermore, tachyphylaxis is addressed and alternatives
are summarised. Finally, recommendations are
presented not to abandon use of metoclopramide in
ICU patients, because metoclopramide is considered
effective in enhancing gastric emptying and facilitating
early enteral nutrition.(but not acute) chemotherapy-induced nausea andIntroduction
In past years, regulatory bodies in North America have
conducted reviews and issued warnings on metoclopra-
mide. The US Food and Drug Administration has required
boxed warnings and a maximum use of 12 weeks since
2009 [1], and a similar warning was issued in Canada in
2011 [2].
In December 2011 the French medicines regulatory
agency L’Agence nationale de sécurité du médicament
et des produits de santé requested a review of metoclo-
pramide by the Committee on Medicinal Products for
Human Use of the European Medicines Agency (EMA)
because of continued safety and efficacy concerns. The
Committee gave its opinion on 26 July 2013, which was
followed by a re-examination requested by a manufac-
turer. This re-examination resulted in December 2013
in recommendations for and restrictions to the use of
metoclopramide to minimise the risk of neurological* Correspondence: zantena@zgv.nl
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for 12 months following its publication. After th
License (http://creativecommons.org/licenses/b
medium, provided the original work is properly
(http://creativecommons.org/publicdomain/zeroand other adverse reactions associated with its use. Im-
posed restrictions included authorisation for short-term
use (up to 5 days) only, lowering the maximum dose for
adults to 30 mg/day or 0.5 mg/kg body weight/day – ir-
respective of the route of administration – and a ban on
its use in patients with chronic conditions such as gas-
troparesis [3].
The formal EMA statement is as follows: ‘In order
to minimise the risks of neurological and other adverse
reactions, metoclopramide should only be prescribed
for short-term use (up to 5 days). It should no longer
be used in chronic conditions such as gastroparesis,
dyspepsia and gastro-oesophageal reflux disease, nor as
an adjunct in surgical and radiological procedures.
In adults, metoclopramide remains indicated for preven-
tion of post-operative nausea and vomiting (PONV),
radiotherapy-induced nausea and vomiting and delayed
vomiting, and for symptomatic treatment of nausea and
vomiting including that associated with acute migraine
(where it may also be used to improve absorption of oral
analgesics)’ [3]. No specific recommendations and re-
strictions for critically ill patients were provided.Why is there a safety issue with metoclopramide?
The EMA recommendations are based on the following
reported side effects in non-ICU patients.
First, neurological adverse reactions, including extra-
pyramidal disorders, dyskinesia, dystonia, convulsion,
hypertonia and tremor, can occur [4]. However, the ab-
solute risk of neurological adverse reactions is poorly
quantified. The reported occurrence of tardive dyskinesia
ranges from <0.01 to 23% [5]. High occurrence is attrib-
uted to chronic use (months to years) of approximately
30 ± 10 mg metoclopramide/day [6] and concerns mostly
older (60 ± 22 years) women [5]. Of an estimated 15.9
million metoclopramide prescriptions in the UK in the
period 1967 to 1982, extrapyramidal symptoms were re-
ported 479 times, representing an incidence of 0.003%.
Of these reactions, 455 were dystonia–dyskinesia, 20entral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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Occurrence of akathisia is related to the rate of intravenous
metoclopramide administration. After a bolus injection
over 2 minutes, 24.7% of patients experienced akathisia,
which was reduced to 5.8% in patients receiving the
same dose in a 15-minute infusion [8]. Acute neuro-
logical adverse reactions in the ICU setting due to single
use or short-term use of metoclopramide have not been
reported in the literature to our knowledge, except for
an anecdotal report on increased intracranial pressure
for a short period after intravenous metoclopramide ad-
ministration [9].
Cardiac adverse reactions, including shock, hypotension,
cardiac arrest, tachycardia, bradycardia, hypertension, car-
diorespiratory arrest and circulatory collapse, can also
occur [4]. Evidence is solely based on case reports. The
available case reports and case series (a total of 56 patients
over a 44-year period) were recently summarised and dis-
cussed [10]. Of those, only three are critically ill pa-
tients. Moreover, the EMA assessment mentions ‘reports’,
but does not refer to any specific publications in its refer-
ences [4].
The need to improve gastrointestinal motility in
critically ill patients
Delayed gastric emptying is commonly encountered in
the ICU and may be present in 50 to 60% of all ICU
patients [11-13]. A recent retrospective analysis in ICUs
from 21 countries demonstrated an enteral feed intoler-
ance among 30.5% of patients after a median 3 days on
enteral nutrition. Prokinetic drugs were administered in
37.9% of cases, primarily metoclopramide and erythro-
mycin far less frequently [14]. Furthermore, enteral feed
intolerance was associated with worse nutrition adequacy
versus the tolerant (56% vs. 64%, P < 0.0001), fewer
ventilator-free days (2.5 vs. 11.2, P < 0.0001), increased
ICU stay (14.4 vs. 11.3 days, P < 0.0001), and increased
mortality (30.8% vs. 26.2, P = 0.04) [14]. Studies such as
the EDEN trial reporting on trophic feeding in contrast to
full feeding have shown noninferior mortality in moder-
ately obese and younger patients with acute respiratory
failure, limiting the generalisability to other ICU patients
[15]. In patients on the full feeding regimen there was a
nonsignificant trend towards better long-term physical
function [16]. Recent data suggest that providing at least
80% of prescribed amounts of protein and calories is asso-
ciated with improved clinical outcomes and thus could be
established as a quality indicator for ICU practice, particu-
larly in high-risk patients [14].
Present use of metoclopramide in critically ill
patients
Metoclopramide is extensively used as an intravenous
prokinetic drug to treat delayed gastric emptying and tofacilitate early enteral feeding. However, metoclopramide
is not officially registered for this specific indication in
critically ill patients.
Off-label use of medications is common in medical
practice. In many countries, off-label use is allowed
when it is based on a firm scientific rationale and on
sound medical evidence, preferably summarised in clinical
practice guidelines [17-19]. However, the legal implica-
tions of clinical practice guidelines are not always clear
[20]. Recently a study found that 79% of off-label prescrip-
tions in primary care lack strong scientific evidence of effi-
cacy [21]. A study in 37 ICUs in the USA in adult patients
found that 36.2% of prescriptions were off-label, one-half
of them with very little or no evidence to support their
use [22].
The commonly used metoclopramide dosage in the
ICU setting is 10 mg four times daily, although 10 mg
three times daily is also used [11]. As tachyphylaxis to
metoclopramide frequently occurs after a few days of
treatment, intravenous erythromycin 200 mg twice daily
can be added to enhance the prokinetic effects and
decrease tachyphylaxis [23]. Early combination therapy of
erythromycin and metoclopramide has been shown to
be more effective than single administration of either
drug [23].
Limited information is available on metoclopramide
dosing in renal failure. It is usually recommended to
reduce the dose by 50% when creatinine clearance is 10
to 50 ml/minute. Since the volume of distribution of
metoclopramide is high, metoclopramide is only minim-
ally removed by haemodialysis or peritoneal dialysis, and
no supplemental dose is necessary after dialysis. During
continuous renal replacement therapy, 50% of the normal
dose can be prescribed [24-26].
Prokinetics and early enteral nutrition
The benefits of early enteral feeding have been docu-
mented with a significant reduction in infectious compli-
cations and a trend towards a reduction in mortality in
critically ill patients, as summarised in the Canadian
Guidelines for Critical Care Nutrition [27,28]. Drugs to
improve gastric emptying that may facilitate early en-
teral nutrition are therefore essential because gastric
intolerance is frequently encountered during enteral
nutritional support in the critically ill [13,14]. In sev-
eral trials, prokinetics have been used prophylactically
to improve feeding efficacy and prevent vomiting and
ventilator-associated pneumonia in general ICU patients
and in patients in the prone position during mechanical
ventilation [29,30].
Since the restrictions imposed by the EMA and others
apply to the approved indications of metoclopramide,
how should these restrictions be translated into use in
critically ill patients?
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metoclopramide?
There appear to be three options regarding the use of
metoclopramide: abandoning the use of metoclopramide
and switching to available alternative(s); adjusting the
dose to the recommended maximum daily dose of 30 mg;
or waiving the imposed restrictions and continuing the
present use of metoclopramide.
Are there (available) alternatives to metoclopramide?
At present in many countries, intravenous erythromycin
is the only available alternative to metoclopramide. Erythro-
mycin is a macrolide antibiotic and, in addition to its
antimicrobial activity, erythromycin is a motilin recep-
tor agonist. As with metoclopramide, the use of erythro-
mycin as a prokinetic drug to improve gastric emptying
is off-label. Erythromycin is generally considered effect-
ive and some investigators suggest that erythromycin is
even more effective than metoclopramide as a single
prokinetic agent [13,31]. Commonly, 200 mg intravenous
erythromycin twice daily is used, but doses of 70 mg
might also be effective [32]. Use of erythromycin as a
single agent may be hampered by the occurrence of
tachyphylaxis within a few days and because of the con-
cerns regarding its cardiac effects (QTc prolongation) and
the potential emergence of antibiotic resistance [11,13].
Besides erythromycin, no other alternatives are cur-
rently available. Several new agents are being developed
but have not yet been studied extensively in critically ill
patients compared with metoclopramide and erythro-
mycin. The following pharmacological agents are being
tested or could be considered.
– Alvimopan and methylnaltrexone are opioid
antagonists that reduce the hospital stay in
postoperative patients and restore bowel function
by antagonising the μ-receptor. Methylnaltrexone
has been reported to improve feed intolerance in a
single study, but alvimopan has not yet been
studied in the critically ill [11,13].
– Ghrelin and its analogue RC-1139 are functionally
related to motilin and accelerate gastric emptying
[33,34]. In animal experiments, additional effects
such as anticatabolic and growth hormone-like
properties have been found. Studies in non-ICU
patients on ghrelin suggest an increase in food
intake and a positive effect on muscle strength
[35,36]. Ghrelin has not yet been studied in the
critically ill. RC-1139 has only proven to be a
potent prokinetic in animal studies [11,13].
– Dexloxiglumide is a cholecystokinin-1 receptor
antagonist. In critically ill patients, cholecystokinin
is an important mediator of delayed gastric
emptying. As a promoter of gastric emptying,dexloxiglumide has been found safe but not always
effective in patients with functional dyspepsia and
irritable bowel syndrome. Dexloxiglumide has not
been tested in ICU patients [11,13].
– Tegaserod is a selective partial 5HT4 receptor
agonist. Clinical improvement has been reported
in an audit of critically ill patients with persistent
feed intolerance [37,38]. The US Food and Drug
Administration withdrew tegaserod from the
market in 2007 for its use as short-term treatment of
constipation-predominant irritable bowel syndrome,
however, because of an increased risk of serious
cardiovascular adverse events. This decision probably
will preclude the use of tegaserod in critically ill
patients [11,13,39].
– TD-8954 is another 5HT4 receptor agonist currently
under investigation [40].
– Mitemcinal and ABT-229 are motilin agonists that
are considered to have the prokinetic effects but
not the antibiotic effects of erythromycin. However,
the effects of ABT-229 have been disappointing,
probably due to tachyphylaxis. Mitemcinal does
accelerate gastric emptying in ambulant patients
with gastroparesis, but has not been investigated in
critically ill patients [11,13]. More recently, another
motilin agonist (GSK 962040) has been tested in
critically ill patients in phase I dosing studies and is
presently in a phase II trial [41].
– Neostigmine is a cholinesterase inhibitor that
increases acetylcholine concentrations at the
neuromuscular junction, thereby enhancing the
intestinal transit time. In a pilot study, a trend
toward accelerated gastric emptying and improved
feed tolerance was observed in critically ill patients
[42]. However, an adequately powered study will be
required to confirm these effects [11].
Adjusting the dose of metoclopramide?
Adjusting the maximum daily dose to 30 mg or 10 mg
three times daily according to the recommendations of
the EMA should decrease the risk of neurological and
other adverse reactions associated with metoclopramide
[1]. However, evidence supporting the effectiveness of
10 mg three times daily in critically ill patients is scarce,
since most studies among these patients investigated the
effects of 10 mg every 6 hours [11]. One study did inves-
tigate metoclopramide 10 mg three times daily in the
prevention of pneumonia in ICU patients who received
enteral feeding through a nasogastric tube [43]. Enteral
feeding via a nasogastric tube has been associated with an
increased risk of ventilator-associated pneumonia, as
impaired gastric emptying may promote migration of gas-
tric microorganisms to the airways. By improving gastric
emptying, metoclopramide is considered to decrease the
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metoclopramide three times daily did delay the onset
of pneumonia in this study, this was shown not to be
of clinical significance because the risk of pneumonia
and mortality were not reduced [43]. Adjusting the meto-
clopramide dosage according to the recommendations of
the EMA can thus not be recommended because there is
a lack of evidence supporting this dosage regimen in crit-
ically ill patients. Efficacy has been shown in studies using
10 mg four times per day [23,31].
Continue the use of metoclopramide as before?
As previously mentioned, intravenous metoclopramide is
frequently used to treat delayed gastric emptying and to
facilitate early enteral feeding, and its off-label use can
be sufficiently supported by documented evidence. Use
of metoclopramide in the ICU is applied only for short
periods (days), limiting the risk of neurological adverse
reactions since these are mainly associated with long-term
use [3,4]. Moreover, the benefits of early enteral feeding
may outweigh the occurrence of nonlife-threatening
side effects.
Tachyphylaxis of prokinetics
In critically ill patients the occurrence of tachyphylaxis
might be more important for successful treatment than
the occurrence of adverse reactions. Tachyphylaxis was
addressed in two studies [23,31]. Treatment was success-
ful when the gastric residue volume remained <250 ml
with a nasogastric feeding rate ≥40 ml/hour. Treatment
failure was defined as two or more high gastric residue
volumes (≥250 ml) within the first 24 hours of treatment
or any 6-hourly gastric residue volume ≥250 ml there-
after. The 7-day effectiveness of intravenous metoclopra-
mide 10 mg four times daily, intravenous erythromycin
200 mg twice per day or combination therapy was inves-
tigated. After 24 hours, successful enteral feeding was
achieved in 62% of patients treated with metoclopra-
mide, in 87% of patients treated with erythromycin and
in almost all (no percentage reported) patients treated
with combination therapy. Over time, however, all
treatments became less effective with treatment failure
(that is, tachyphylaxis) occurring after 2 days, 3 days and
6.5 days for metoclopramide, erythromycin and combin-
ation therapy, respectively. At day 7 of treatment, success-
ful feeding was achieved in 16% of patients treated with
metoclopramide and in 31% of patients treated with
erythromycin. No percentage is known for the com-
bination treatment, but the rate of successful feeding was
significantly higher than treatment with erythromycin as a
single agent.
Desensitisation, downregulation and endocytosis of
neurohumoral receptors have been proposed as mecha-
nisms underlying the occurrence of tachyphylaxis [23,31].Combination therapy is more effective because of the
complementary actions of both prokinetics and the mul-
tiple mechanisms underlying delayed gastric emptying.
The relevance of tachyphylaxis is still unknown, since
combination therapy associated with delayed occur-
rence of tachyphylaxis did not result in improved sur-
vival or length of hospital stay. However, the power
of the study might be insufficient to demonstrate sig-
nificance [23,31].Recommendation and future perspectives
At present, the only available alternative to metoclopra-
mide that has been extensively studied in critically ill pa-
tients is erythromycin, but both agents are commonly
used as a combined strategy to improve gastric emptying
and improve patient outcomes [11]. Some new prokinetic
agents appear promising, but need testing in critically
ill patients and therefore will not be available in the near
future.
Weighing all of the pros and cons and considering all
relevant aspects involved, we recommend to continue the
off-label use of metoclopramide in critically ill patients
and not to exceed a daily dose of 10 mg four times. Atten-
tion must be paid to the reported side effects and the oc-
currence of tachyphylaxis, since this might be of major
importance for patient safety and successful treatment.
If intolerance to enteral feeding persists with use of
metoclopramide, erythromycin should be added for an-
other 24 to 48 hours. If this combination does not work,
in our opinion it is probably better to stop both agents
and move to another route of feeding such as postpylo-
ric feeding. In any case, we recommend using the com-
bination only during a maximum of 7 days to limit side
effects related to prolonged exposure and for reasons of
tachyphylaxis. In cases of renal failure, the dose of meto-
clopramide should be adjusted.
We hope that new prokinetics will come to the market
with high effectivity, limited or absent tachyphylaxis and
no serious side effects.
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EMA: European medicines agency.
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